NCT00691808

Study of LX6171 in Elderly Volunteers With Age Associated Memory Impairment

A Randomized, Double-Blind, Placebo-Controlled Study to Determine Safety and Tolerability of LX6171 Oral Suspension Dosed for 28 Days in Subjects Exhibiting Age Associated Memory Impairment (AAMI)

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 103 (actual)
• Sponsor: Lexicon Pharmaceuticals · Industry
• Sex: All
• Age: 60 Years – 80 Years
• Healthy volunteers: Not accepted

Summary

The purpose of the study is to determine the safety, tolerability, and effectiveness of 2 dose levels of LX6171 given over 28 days in patients with Age Associated Memory Impairment (AAMI).

Conditions

• Age-Related Memory Disorders

Interventions

Type	Name	Description
DRUG	LX6171 High Dose	A high dose of LX6171, using an oral suspension; daily oral intake for 28 days in the morning at approximately the same time.
DRUG	LX6171 Low Dose	A low dose of LX6171, using an oral suspension; daily oral intake for 28 days in the morning at approximately the same time.
DRUG	Placebo	Matching placebo dosing with daily oral intake for 28 days in the morning at approximately the same time.

Timeline

• Start date: 2008-02-01
• Primary completion: 2008-10-01
• First posted: 2008-06-05
• Last updated: 2010-03-03
• Results posted: 2010-03-03

Locations

2 sites across 1 country: Netherlands